-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3.7%
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3.7%
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands during trading, a decline of 100% from the average daily volume of 237,348 shares. The stock had previously closed at $7.51.
Analyst Ratings Changes
Several research analysts have recently commented on TNGX shares. Wedbush raised their price target on Tango Therapeutics to $21.00 in a research report on Wednesday, November 16th. HC Wainwright upgraded Tango Therapeutics from a "neutral" rating to a "buy" rating in a research note on Thursday, October 20th.
Get Tango Therapeutics alerts:Tango Therapeutics Price Performance
The company has a market capitalization of $690.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.85. The stock has a 50 day simple moving average of $7.58 and a two-hundred day simple moving average of $5.46.
Insider Buying and Selling at Tango Therapeutics
In other Tango Therapeutics news, major shareholder Boxer Capital, Llc purchased 70,394 shares of the business's stock in a transaction on Thursday, October 6th. The shares were bought at an average cost of $4.06 per share, for a total transaction of $285,799.64. Following the completion of the purchase, the insider now directly owns 7,053,642 shares in the company, valued at $28,637,786.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 283,000 shares of company stock worth $1,202,524 over the last ninety days. Corporate insiders own 3.70% of the company's stock.Institutional Trading of Tango Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. Alaethes Wealth LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $91,000. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $78,000. Ensign Peak Advisors Inc grew its holdings in shares of Tango Therapeutics by 183.4% during the second quarter. Ensign Peak Advisors Inc now owns 299,391 shares of the company's stock worth $1,356,000 after buying an additional 193,735 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics during the first quarter worth about $113,000. Finally, FMR LLC grew its holdings in shares of Tango Therapeutics by 11.0% during the second quarter. FMR LLC now owns 7,631,917 shares of the company's stock worth $34,572,000 after buying an additional 755,942 shares during the last quarter. Institutional investors and hedge funds own 77.30% of the company's stock.
Tango Therapeutics Company Profile
(Get Rating)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands during trading, a decline of 100% from the average daily volume of 237,348 shares. The stock had previously closed at $7.51.
探戈治疗公司(纳斯达克代码：TNGX-GET评级)的股票在周五的交易中上涨了3.7%。该股一度涨至7.79美元，最新报7.79美元。约有651股股票在交易中易手，较日均成交量237,348股下降了100%。该股此前收盘价为7.51美元。
Analyst Ratings Changes
分析师评级发生变化
Several research analysts have recently commented on TNGX shares. Wedbush raised their price target on Tango Therapeutics to $21.00 in a research report on Wednesday, November 16th. HC Wainwright upgraded Tango Therapeutics from a "neutral" rating to a "buy" rating in a research note on Thursday, October 20th.
几位研究分析师最近对TNGX的股票发表了评论。韦德布什在11月16日星期三的一份研究报告中将他们对Tango治疗公司的目标价上调至21.00美元。在10月20日星期四的一份研究报告中，HC Wainwright将Tango治疗公司的评级从中性上调至买入。
Tango Therapeutics Price Performance
探戈治疗药物性价比
The company has a market capitalization of $690.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.85. The stock has a 50 day simple moving average of $7.58 and a two-hundred day simple moving average of $5.46.
该公司市值为6.9045亿美元，市盈率为-6.81倍，贝塔系数为1.85。该股的50日简单移动均线切入位为7.58美元，200日简单移动均线切入位为5.46美元。
Insider Buying and Selling at Tango Therapeutics
Tango治疗公司的内幕买卖
Institutional Trading of Tango Therapeutics
探戈治疗的制度性交易
A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. Alaethes Wealth LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $91,000. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $78,000. Ensign Peak Advisors Inc grew its holdings in shares of Tango Therapeutics by 183.4% during the second quarter. Ensign Peak Advisors Inc now owns 299,391 shares of the company's stock worth $1,356,000 after buying an additional 193,735 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics during the first quarter worth about $113,000. Finally, FMR LLC grew its holdings in shares of Tango Therapeutics by 11.0% during the second quarter. FMR LLC now owns 7,631,917 shares of the company's stock worth $34,572,000 after buying an additional 755,942 shares during the last quarter. Institutional investors and hedge funds own 77.30% of the company's stock.
一些对冲基金和其他机构投资者最近改变了他们在TNGX的头寸。Alaethes Wealth LLC在第二季度购买了Tango治疗公司新的股票头寸，价值约91,000美元。SG America Securities LLC在第二季度购买了Tango治疗公司新的股票头寸，价值约7.8万美元。Ensign Peak Advisors Inc.在第二季度增持了探戈治疗公司的股票183.4%。Ensign Peak Advisors Inc.现在拥有299,391股该公司股票，价值1,356,000美元，此前该公司在上个季度又购买了193,735股。GSA Capital Partners LLP在第一季度购买了Tango治疗公司新的股票头寸，价值约11.3万美元。最后，FMR LLC在第二季度增持了Tango治疗公司的股票11.0%。FMR LLC现在拥有该公司7,631,917股股票，价值34,572,000美元，上个季度又购买了755,942股。机构投资者和对冲基金持有该公司77.30%的股票。
Tango Therapeutics Company Profile
探戈治疗公司简介
(Get Rating)
(获取评级)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
探戈治疗公司是一家生物技术公司，负责发现和开发治疗癌症的药物。它的主要项目是TNG908，一种合成的精氨酸甲基转移酶5的致命小分子抑制剂，正在开发用于治疗甲基硫代腺苷磷酸化酶缺失的癌症。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免费获取StockNews.com关于探戈治疗(TNGX)的研究报告
- MarketBeat：回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温，标普500指数何去何从
- Cintas以经营杠杆击败通胀
- 你买下Palantir的决定可能只是个时间问题
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《探戈治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tango治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧